Assessing Quality of Life in Patients Undergoing Allogeneic Stem Cell Transplantation
the Cancer Therapy Advisor take:
Health-related quality of life (HRQL) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was linked to whether the transplant was after myeloablative conditioning (MAC) or reduced intensity conditioning (RIC), according to an article posted online in the European Journal of Cancer Care.
Participants included 94 patients who were undergoing HSCT after MAC (n = 18) or RIC (n= 76). The EORTC QLQ C-30 was used to assess HRQL in patients during the inpatient period and throughout the following 3 years.
Patients’ functional status and global quality of life (eg, role,social functions) were observed to have decreased from baseline to weeks 2 and 3.
Symptoms including appetite loss, nausea and vomiting, diarrhea and fatigue significantly increased during the first 3 weeks.
HRQL took at least 1 year to return to baseline level, but only role function was found to have significantly improved 3 years post-transplantation.
Patients who initially received MAC had a significantly worse HRQL at baseline, along with patients with extensive chronic graft-versus-host disease. Patients who received MAC also experienced more pain, interrupted sleep, and appetite loss in weeks 3 and 4 compared to those who received RIC.
Quality of life linked to whether the transplant was after myeloablative conditioning or reduced intensity conditioning.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma